

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Single Technology Appraisal**

**Larotrectinib for treating NTRK fusion-positive advanced solid tumours  
(Managed access review of TA630) [ID6292]**

**Final Stakeholder List**

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Bayer (larotrectinib)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Action Kidney Cancer</li> <li>• Anthony Pilcher Bone Cancer Trust</li> <li>• Asthma + Lung Foundation</li> <li>• Black Health Agency for Equality</li> <li>• Bob Champion Cancer Trust</li> <li>• Bowel Cancer UK</li> <li>• Breast Cancer Now</li> <li>• Breast Cancer UK</li> <li>• British Skin Foundation</li> <li>• Butterfly Thyroid Cancer Trust</li> <li>• Cancer 52</li> <li>• Cancer Black Care</li> <li>• Cancer Laryngectomy Trust</li> <li>• Changing Faces</li> <li>• Childhood Cancer Parents Alliance</li> <li>• Children's Cancer and Leukaemia Group</li> <li>• Children with Cancer</li> <li>• Genetic Alliance UK</li> <li>• Get-A-Head</li> <li>• GIST Cancer UK</li> <li>• Helen Rollason Cancer Charity</li> <li>• Independent Cancer Patients Voice</li> <li>• Kidney Cancer UK</li> <li>• Kidney Care UK</li> <li>• Kidney Research UK</li> <li>• Let's Face It</li> <li>• Macmillan Cancer Support</li> <li>• Maggie's Centres</li> <li>• Marie Curie</li> <li>• Mouth Cancer Foundation</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health - Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Confederation</li> <li>• NHS Wales Joint Commissioning Committee</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Government</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• None</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Against Breast Cancer</li> <li>• Bone Cancer Research Trust</li> <li>• Bone Research Society</li> <li>• Breast Cancer Hope</li> <li>• Breast Cancer Research Trust</li> <li>• Cochrane Breast Cancer Group</li> <li>• Cochrane Childhood Cancer Group</li> <li>• Cochrane Lung Cancer Group</li> <li>• Cochrane Prostatic Diseases Urologic Cancers Group</li> <li>• Cochrane Skin Group</li> <li>• Genomics England</li> </ul>

Final stakeholder list for the evaluation of larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]

Issue date: August 2025

© National Institute for Health and Care Excellence 2025. All rights reserved. 1 of 4

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• National Association of Laryngectomee Clubs</li> <li>• National Kidney Federation</li> <li>• NTRKers</li> <li>• Orchid – Fighting Male Cancer</li> <li>• OUTpatients</li> <li>• Prostate Cancer UK</li> <li>• Roy Castle Lung Cancer Foundation</li> <li>• Sarcoma UK</li> <li>• Solving Kid's Cancer</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Swallows Head and Neck Cancer Support Group</li> <li>• Teenage Cancer Trust</li> <li>• Tenovus Cancer Care</li> <li>• The Royal Marsden Cancer Charity</li> <li>• Together for Short Lives</li> <li>• UK Lung Cancer Coalition</li> <li>• Women's Health Concern</li> <li>• Young Lives vs Cancer</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Anaesthetists</li> <li>• Association of Cancer Physicians</li> <li>• Association of Respiratory Nurse Specialists</li> <li>• Association of Surgeons of Great Britain and Ireland</li> <li>• British Association of Dermatologists</li> <li>• British Association of Endocrine and Thyroid Surgeons</li> <li>• British Association of Surgical Oncology</li> <li>• British Association of Urological Surgeons</li> <li>• British Dermatological Nursing Group</li> <li>• British Geriatrics Society</li> <li>• British Institute of Radiology</li> <li>• British Oncology Pharmacy Association</li> <li>• British Orthopaedic Association</li> <li>• British Orthopaedic Oncology Society</li> <li>• British Psychosocial Oncology Society</li> </ul>	<ul style="list-style-type: none"> <li>• Institute of Cancer Research</li> <li>• Melanoma Fund</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> <li>• Oracle Cancer Trust</li> <li>• Pro Cancer Research Fund</li> <li>• Prostate Cancer Research Centre</li> <li>• Research Institute for the Care of Older People</li> <li>• Skin Cancer Research Fund</li> <li>• Skin Treatment &amp; Research Trust</li> </ul> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>• Public Health Wales</li> <li>• UK Health Security Agency</li> </ul>

Final stakeholder list for the evaluation of larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]

Issue date: August 2025

© National Institute for Health and Care Excellence 2025. All rights reserved. 2 of 4

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>British Sarcoma Group</li> <li>British Society for Dermatological Surgery</li> <li>British Society of Skeletal Radiologists</li> <li>British Society of Urogenital Radiology</li> <li>British Thoracic Oncology Group</li> <li>British Thoracic Society</li> <li>British Thyroid Association</li> <li>British Uro-oncology Group</li> <li>Cancer Research UK</li> <li>CCLG: The Children &amp; Young People's Cancer Association</li> <li>Lung Cancer Nursing UK</li> <li>Melanoma Focus</li> <li>Pelican Cancer Foundation</li> <li>Primary Care Dermatology Society</li> <li>Royal College of Anaesthetists</li> <li>Royal College of General Practitioners</li> <li>Royal College of Nursing</li> <li>Royal College of Paediatricians and Child Health</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal College of Radiologists</li> <li>Royal College of Surgeons</li> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine</li> <li>Society and College of Radiographers</li> <li>UK Clinical Pharmacy Association</li> <li>UK Kidney Association</li> <li>UK Oncology Nursing Society</li> <li>UK Renal Pharmacy Group</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>Department of Health and Social Care</li> <li>NHS England</li> </ul>	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

## Definitions:

Final stakeholder list for the evaluation of larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]

Issue date: August 2025

© National Institute for Health and Care Excellence 2025. All rights reserved. 3 of 4

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.